We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.96%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.19B
AUM Growth
-$667M
Cap. Flow
-$151M
Cap. Flow %
-3.6%
Top 10 Hldgs %
47.69%
Holding
131
New
13
Increased
16
Reduced
22
Closed
21

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$101M
2
SION
Sionna Therapeutics
SION
+$60.5M
3
AXSM icon
Axsome Therapeutics
AXSM
+$44.1M
4
APLS
Apellis Pharmaceuticals
APLS
+$39.6M
5
UNH icon
UnitedHealth
UNH
+$35.9M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$117M
2
MRK icon
Merck
MRK
+$82.6M
3
BIIB icon
Biogen
BIIB
+$77.9M
4
ISRG icon
Intuitive Surgical
ISRG
+$61.2M
5
UHS icon
Universal Health Services
UHS
+$48.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIR icon
51
Vir Biotechnology
VIR
$1.49B
$14.6M 0.35%
2,248,249
-970,368
-30% -$8.63M
CGEM icon
52
Cullinan Oncology
CGEM
$1.07B
$14.6M 0.35%
1,923,855
-18,700
-1% -$179K
IMTX icon
53
Immatics
IMTX
$1.19B
$13.9M 0.33%
3,087,462
– –
AMGN icon
54
Amgen
AMGN
$212B
$13.8M 0.33%
+44,200
New +$13.1M
PFE icon
55
CALL
Pfizer
PFE
$144B
$12.7M 0.3%
500,000
+250,000
+100% +$6.54M
VERA icon
56
Vera Therapeutics
VERA
$2.39B
$11.6M 0.28%
481,065
-261,507
-35% -$8.4M
GPCR icon
57
Structure Therapeutics
GPCR
$3.4B
$11.3M 0.27%
652,028
– –
CCCC icon
58
C4 Therapeutics
CCCC
$393M
$10.9M 0.26%
6,830,300
+2,452,400
+56% +$7.31M
DYN icon
59
Dyne Therapeutics
DYN
$4.28B
$10.6M 0.25%
1,014,611
-212,469
-17% -$3.04M
KROS icon
60
Keros Therapeutics
KROS
$199M
$10.4M 0.25%
1,018,734
– –
SLRN
61
DELISTED
ACELYRIN
SLRN
$9.88M 0.24%
4,001,711
– –
AGIO icon
62
Agios Pharmaceuticals
AGIO
$2.14B
$9.54M 0.23%
325,500
+298,800
+1,119% +$9.91M
ABCL icon
63
AbCellera Biologics
ABCL
$1.62B
$9.32M 0.22%
4,180,768
– –
ACET icon
64
Adicet Bio
ACET
$76.7M
$8.64M 0.21%
715,446
– –
ADCT icon
65
ADC Therapeutics
ADCT
$141M
$8.42M 0.2%
5,968,451
– –
PRLD icon
66
Prelude Therapeutics
PRLD
$370M
$8.38M 0.2%
10,909,256
– –
XBI icon
67
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$8.11M 0.19%
+100,000
New +$8.94M
AVTX icon
68
Avalo Therapeutics
AVTX
$1.03B
$7.75M 0.18%
967,000
– –
SWTX
69
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$7.62M 0.18%
+172,600
New +$7.95M
WHWK
70
Whitehawk Therapeutics
WHWK
$182M
$7.42M 0.18%
+4,166,000
New +$10.9M
AKRO
71
DELISTED
Akero Therapeutics
AKRO
$7.28M 0.17%
179,900
+113,900
+173% +$4.83M
PMVP icon
72
PMV Pharmaceuticals
PMVP
$58.7M
$7.06M 0.17%
6,475,291
– –
TRVI icon
73
Trevi Therapeutics
TRVI
$2.62B
$7.04M 0.17%
+1,120,000
New +$5.34M
KMTS
74
Kestra Medical Technologies
KMTS
$1.4B
$6.23M 0.15%
+250,000
New +$5.74M
CRBP icon
75
Corbus Pharmaceuticals
CRBP
$168M
$6.22M 0.15%
1,172,287
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q1 2025 Portfolio in Review

As of Q1 2025, OrbiMed held 131 positions worth $4.19B, down 14% from $4.86B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

OrbiMed withdrew a net $151M in Q1 2025, closing 21 positions and reducing 22 holdings. Its most notable exit was Sarepta Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, OrbiMed opened a new position in Pfizer worth $97.6M.

  • OrbiMed's largest Q1 2025 buy was Pfizer: 3,850,200 shares worth $97.6M.
  • OrbiMed added most to UnitedHealth in Q1 2025, an estimated $35.9M increase.
  • OrbiMed's biggest Q1 2025 reduction was Intuitive Surgical, cutting an estimated $61.2M.
  • OrbiMed fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $117M.
  • OrbiMed's ten largest holdings make up 48% of its $4.19B portfolio in Q1 2025.
  • OrbiMed opened 13 new positions and closed 21 in Q1 2025.
  • OrbiMed's portfolio value fell 14% quarter-over-quarter to $4.19B.

Based on OrbiMed's 13F filing for Q1 2025, filed 15 May 2025.